Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of NBP615 Vaccine in Healthy Females
NCT04453241Phase 2Completed
- Sponsor
- SK bioscience
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Human papillomavirus L1 virus-like particles vaccine NBP615 in Cervical Cancer (CC), sponsored by SK bioscience. Started Dec 2018; status: completed.
02
Drugs
Human papillomavirus L1 virus-like particles vaccine NBP615
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04453241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04453241.